DaVita, Inc. (NYSE:DVA)

CAPS Rating: 3 out of 5

The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.

Recs

0
Player Avatar pharos60 (67.80) Submitted: 1/1/2007 10:22:09 PM : Outperform Start Price: $56.70 DVA Score: +45.63

Kidney dialysis is a business with no end in sight. Recent acquisition of Gambro's clinics is a can't lose proposition

Featured Broker Partners


Advertisement